NCT02647554View on ClinicalTrials.gov

Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China

PHASE4CompletedINTERVENTIONAL
Enrollment

347

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

May 1, 2021

Study Completion Date

August 1, 2021

Conditions
SepsisSeptic Shock
Interventions
DRUG

ulinastatin

ulinastatin 400,000 IU every 8 hours for 10 days

DRUG

Placebo

matching placebo every 8 hours for 10 days

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Techpool Bio-Pharma Co., Ltd.

INDUSTRY

lead

Peking Union Medical College Hospital

OTHER

NCT02647554 - Ulinastatin Treatment in Adult Patients With Sepsis and Septic Shock in China | Biotech Hunter | Biotech Hunter